Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism
Authors' conclusion
Rheumatologic control was generally maintained, particularly when rheumatologic treatment was initiated first. Pulmonary infections were the main adverse events
Study context
- Population
- Patients treated with dual targeted therapies for chronic inflammatory rheumatism (CIR) and asthma, December 2020 to June 2023, multiple French hospital centres19 therapeutic combinations
- Participants
- 16 patients
- Outcome
- Impact of the combination on the course of both chronic inflammatory diseases and their safety profile
Methodological detailscase series, multicentre
- Case series
- Multicentre
Main finding
As reported in the abstract
- Mean duration of dual therapy (months)
- 14.2 ± 8.4
- Combinations requiring modification of rheumatologic treatment
- 4 (21.1%)
- Rheumatologic treatment modified for inadequate disease control
- 3 (15.8%)
- Rheumatologic treatment modified for remission of CIR
- 1 (5.25%)
- Combinations modified for poor asthma control
- 3 (15.8%)
Observational data: associations, not effects.
Safety
Adverse events
- Combinations associated with AEs
- 11 out of 19 (57.9%)
- Serious events
- 7 (63.6%)
- Respiratory infections (most frequent)
- 5
- Combinations modified due to AEs
- 3 (15.8%)
Original publication
Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism. Joint Bone Spine. Published 19 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →